Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
New England Journal of Medicine · 13.04.2023 · 388 (15) · 1353-1364
DOI: 10.1056/nejmoa2215024 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 13.04.2023. Verfasst von Steven E Nissen und 29 weiteren Autor:innen. Beteiligte Einrichtung: From the Cleveland Clinic, Cleveland (S.E.N., A.M.L., D.B., D.M., L.C., V.M., J.M., D.D.); Imperial College London, London (K.K.R.); University of Am…. Hauptthemen laut MEDLINE: Cardiovascular Diseases. Die Arbeit wurde bisher 984-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Esperion Therapeutics.
Abstract (Originalsprache)
BACKGROUND: Bempedoic acid, an ATP citrate lyase inhibitor, reduces low-density lipoprotein (LDL) cholesterol levels and is associated with a low incidence of muscle-related adverse events; its effects on cardiovascular outcomes remain uncertain. METHODS: We conducted a double-blind, randomized, placebo-controlled trial involving patients who were unable or unwilling to take statins owing to unacceptable adverse effects ("statin-intolerant" patients) and had, or were at high risk for, cardiovascular disease. The patients were assigned to receive oral bempedoic acid, 180 mg daily, or placebo. The primary end point was a four-component composite of major adverse cardiovascular events, defined as death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization. RESULTS: A total of 13,970 patients underwent randomization; 6992 were assigned to the bempedoic acid group and 6978 to the placebo group. The median duration of follow-up was 40.6 months. The mean LDL cholesterol level at baseline was 139.0 mg per deciliter in both groups, and after 6 months, the reduction in the level was greater with bempedoic acid than with placebo by 29.2 mg per deciliter; the observed difference in the percent reductions was 21.1 percentage points in favor of bempedoic acid. The incidence of a primary end-point event was significantly lower with bempedoic acid than with placebo (819 patients [11.7%] vs. 927 [13.3%]; hazard ratio, 0.87; 95% confidence interval [CI], 0.79 to 0.96; P = 0.004), as were the incidences of a composite of death from cardiovascular causes, nonfatal stroke, or nonfatal myocardial infarction (575 [8.2%] vs. 663 [9.5%]; hazard ratio, 0.85; 95% CI, 0.76 to 0.96; P = 0.006); fatal or nonfatal myocardial infarction (261 [3.7%] vs. 334 [4.8%]; hazard ratio, 0.77; 95% CI, 0.66 to 0.91; P = 0.002); and coronary revascularization (435 [6.2%] vs. 529 [7.6%]; hazard ratio, 0.81; 95% CI, 0.72 to 0.92; P = 0.001). Bempedoic acid had no significant effects on fatal or nonfatal stroke, death from cardiovascular causes, and death from any cause. The incidences of gout and cholelithiasis were higher with bempedoic acid than with placebo (3.1% vs. 2.1% and 2.2% vs. 1.2%, respectively), as were the incidences of small increases in serum creatinine, uric acid, and hepatic-enzyme levels. CONCLUSIONS: Among statin-intolerant patients, treatment with bempedoic acid was associated with a lower risk of major adverse cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization). (Funded by Esperion Therapeutics; CLEAR Outcomes ClinicalTrials.gov number, NCT02993406.).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Cleveland Clinic, Cleveland (S.E.N., A.M.L., D.B., D.M., L.C., V.M., J.M., D.D.); Imperial College London, London (K.K.R.); University of Amsterdam Academic Medical Center, Amsterdam (J.J.P.K.), and University…
ORCID-Profile: Steven E Nissen, Kausik K Ray, John J P Kastelein
Förderung
- Esperion Therapeutics
Zitieren
APA
Nissen, S. E., Lincoff, A. M., Brennan, D., Ray, K. K., Mason, D., Kastelein, J. J. P., Thompson, P. D., Libby, P., Cho, L., Plutzky, J., Bays, H. E., Moriarty, P. M., Menon, V., Grobbee, D. E., Louie, M. J., Chen, C. F., Li, N., Bloedon, L., Robinson, P., …, & CLEAR Outcomes Investigators (2023). Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. New England Journal of Medicine, 388(15), 1353-1364. https://doi.org/10.1056/nejmoa2215024
Vancouver
Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. New England Journal of Medicine. 2023;388(15):1353-1364. doi:10.1056/nejmoa2215024
BibTeX
@article{Nissen2023,
author = {Nissen, Steven E and Lincoff, A Michael and Brennan, Danielle and Ray, Kausik K and Mason, Denise and Kastelein, John J P and Thompson, Paul D and Libby, Peter and Cho, Leslie and Plutzky, Jorge and Bays, Harold E and Moriarty, Patrick M and Menon, Venu and Grobbee, Diederick E and Louie, Michael J and Chen, Chien-Feng and Li, Na and Bloedon, LeAnne and Robinson, Paula and Horner, Maggie and Sasiela, William J and McCluskey, Jackie and Davey, Deborah and Fajardo-Campos, Pedro and Petrovic, Predrag and Fedacko, Jan and Zmuda, Witold and Lukyanov, Yury and Nicholls, Stephen J and CLEAR Outcomes Investigators, CLEAR Outcomes Investigators},
title = {Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients},
journal = {New England Journal of Medicine},
year = {2023},
volume = {388},
number = {15},
pages = {1353--1364},
doi = {10.1056/nejmoa2215024}
}
EUVIMED